Aims and objects. To develop a coordinated scientific framework to assess phytopharmaceuticals. To promote acceptance of phytopharmaceuticals, especially within the therapy of general medical practitioners. To support and initiate clinical and experimental research in phytotherapy. To improve and extend the international accumulation of scientific and practical knowledge.
National associations represented.
Federal Republic of Germany: Gesellschaft fu?r Phytotherapie e.V.
The Netherlands: Nederlandse Vereniging voor Fytotherapie.
Belgium: Socie?te? Belge de Phytothe?rapie, Belgische Vereniging voor Phytotherapie. France: Institut Francais de Phytothe?rapie.
United Kingdom: British Herbal Medicine Association.
Switzerland: Schweizerische Medizinische Gesellschaft fu?r Phytotherapie.
The Scientific Committee, with two delegates from each member country, has embarked on a programme of compiling proposals for European monographs on the medicinal uses of plant drugs. This task is expected to take about ten years to complete.
In preparing monographs the Committee assesses information from published scientific literature together with national viewpoints as expressed by delegates or included in the results of national reviews. Leading researchers on specific plant drugs are invited to relevant meetings and their contributions substantially assist the Committee’s work. Draft monographs prepared by the Scientific Committee are circulated for appraisal and comment to an independent Board of Supervising Editors, which includes eminent academic experts in the field of phytotherapy.
The monographs are offered to regulatory authorities as a means of harmonising the medicinal uses of plant medicines within the EC and in a wider European context. Phytotherapy (Herbalism) makes an important contribution to European medicine.